Standpoint Research Upgrades Teva Pharma (TEVA) to Buy
Tweet
Share
E-mailGet Alerts TEVA Hot Sheet
Price: $12.78 -3.03%
Rating Summary:
12 Buy, 25 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 10 | New: 5
Rating Summary:
12 Buy, 25 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 10 | New: 5
Join SI Premium – FREE
Standpoint Research upgraded Teva Pharma (NYSE: TEVA) from Hold to Buy with a price target of $65.00.
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $49.86 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
- Teva Pharma (TEVA) and Teva (TEVA) Announce FDA Approval of SELARSDI
- Wolfe Research Upgrades Bank of America (BAC) to Outperform
Create E-mail Alert Related Categories
UpgradesRelated Entities
Standpoint ResearchSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
